Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.
10 Oct 2023
License out/inDrug Approval
LONDON--(BUSINESS WIRE)-- Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals.
“As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatments, we are excited to acquire new products to expand our Menopause portfolio.” - Rob Stewart, CEO of Theramex.
Duphaston® (dydrogesterone) and Femoston® (estradiol/dydrogesterone) may be prescribed in indications related to hormone replacement therapy (HRT).
About Theramex
Theramex is a leading, global specialty pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, Theramex supports women at different stages of their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing innovative, effective solutions that care for and support women as they advance through each stage of their lives. To learn more about Theramex, please visit .
View source version on businesswire.com:
Contacts
For further information about Theramex, please contact:
Katja Lundell, Senior Director, Global Head of Policy, Pricing and Communications.
Email: Katja.Lundell@theramex.com
Phone : +44 203 962 5555
THX_HQ_PRESSR_011393
Source: Theramex
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.